市场快照
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| CAGR: | 6.4 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
所研究的市场主要受诸如胰腺癌患病率增加、对该疾病的诊断测试和治疗需求增加等因素的推动。因此，许多政府和非营利组织已采取主动行动，在亚太地区传播对胰腺癌的认识。此外，诊断和治疗方面的技术进步带来了更有效的解决方案。这些是推动市场增长的主要因素。
治疗和诊断的高成本以及治疗引起的副作用预计将抑制市场增长。
报告范围
当胰腺的一部分开始不受控制的细胞生长时，就会发生胰腺癌。肿瘤会发展，这些会干扰胰腺的工作方式。胰腺癌治疗和诊断涉及成功诊断和治疗胰腺癌的程序。
在报告中，提供了对亚太地区胰腺癌治疗和诊断市场的详细分析。通过整理跨部门产生的收入来评估市场，这些收入按癌症类型、治疗、诊断和地理分类。
| By Type | ||||||
| ||||||
|
| By Cancer Type | |
| Exocrine Cancers | |
| Endocrine Cancers |
| Geography | ||||||||
|
主要市场趋势
放射治疗有望实现高复合年增长率
放射疗法是一种癌症治疗方法，它使用高能辐射，以波（如 X 射线）或粒子（如质子）的形式来杀死癌细胞或阻止它们生长和分裂。放射治疗可以防止胰腺肿瘤生长，有时可以缩小它们。由于放射治疗针对特定（集中）区域，因此被认为是局部治疗。
正如 Noorazrul Yahya 等人在亚太临床肿瘤学杂志上发表的 2018 年报告所述，亚太地区对放射治疗的需求预计也会增加。根据该报告的估计，预计 2025 年和 2035 年所需的放射治疗分数将分别增加到 1110 万和 1410 万，而东南亚 2015 年为 760 万。
随着需求的增加，预计其在胰腺癌中的应用也会增加。预计这将有助于该地区的市场增长。
To understand key trends, Download Sample Report
竞争格局
亚太地区大部分国家都是发展中国家。这些发展中经济体的胰腺癌患病率越来越高。因此，这些国家对于全球参与者进入市场来说是非常有利可图的。因此，该地区拥有胰腺癌治疗和诊断市场中全球最大的参与者。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
-
4.2.2 Rising Awareness and Concern about the Disease
-
4.2.3 Technological Advancements and Innovation of New Products
-
-
4.3 Market Restraints
-
4.3.1 High Costs Associated with Treatment and Diagnosis
-
4.3.2 Side Effects of Pancreatic Cancer Therapy
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Type
-
5.1.1 By Treatment
-
5.1.1.1 Surgery
-
5.1.1.2 Chemotherapy
-
5.1.1.3 Radiation Therapy
-
5.1.1.4 Targeted Therapy
-
-
5.1.2 By Diagnostics
-
5.1.2.1 Imaging
-
5.1.2.2 Biopsy
-
5.1.2.3 Endoscopy
-
5.1.2.4 Other Diagnostic Tests
-
-
-
5.2 By Cancer Type
-
5.2.1 Exocrine Cancers
-
5.2.2 Endocrine Cancers
-
-
5.3 Geography
-
5.3.1 Asia-Pacific
-
5.3.1.1 China
-
5.3.1.2 Japan
-
5.3.1.3 India
-
5.3.1.4 Australia
-
5.3.1.5 South Korea
-
5.3.1.6 Rest of Asia-Pacific
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 Bristol-Myers Squibb
-
6.1.2 Canon Medical Systems
-
6.1.3 Eli Lilly and Company
-
6.1.4 F. Hoffmann-La Roche AG
-
6.1.5 GE Healthcare
-
6.1.6 Hitachi Medical
-
6.1.7 Novartis AG
-
6.1.8 Pfizer Inc
-
6.1.9 Philips Healthcare
-
6.1.10 Siemens AG
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.
What is the growth rate of Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market?
The Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 6.4% over the next 5 years.
Who are the key players in Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market?
Bristol-Myers Squibb, Novartis AG, F. Hoffmann-La Roche AG, Pfizer Inc, Eli Lilly and Company are the major companies operating in Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market.
